The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback